Trial · NCT06634797
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2) | mRNA-1273.712 | 1 | Participants | ||
| Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2) | Placebo | 0 | Participants | ||
| Number of Participants With Elevated cTnI Level at Day 1 (Baseline) | Sequence 1: mRNA-1273.712 Then Placebo | 2 | Participants | ||
| Number of Participants With Elevated cTnI Level at Day 1 (Baseline) | Sequence 2: Placebo Then mRNA-1273.712 | 5 | Participants | ||
| Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2) | mRNA-1273.712 | 4 | Participants | ||
| Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2) | Placebo | 8 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): mRNA-1273.712 | SAEs | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): Placebo | SAEs | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 2 (Placebo - mRNA-1273.712): Placebo | SAEs | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 2 (Placebo - mRNA-1273.712): mRNA-1273.712 | SAEs | 1 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): mRNA-1273.712 | MAAEs | 6 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): Placebo | MAAEs | 5 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 2 (Placebo - mRNA-1273.712): Placebo | MAAEs | 9 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 2 (Placebo - mRNA-1273.712): mRNA-1273.712 | MAAEs | 10 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): mRNA-1273.712 | AESIs | 1 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): Placebo | AESIs | 1 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 2 (Placebo - mRNA-1273.712): Placebo | AESIs | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 2 (Placebo - mRNA-1273.712): mRNA-1273.712 | AESIs | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): mRNA-1273.712 | AEs Leading to Study Discontinuation | 0 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal | Sequence 1 (mRNA-1273.712 - Placebo): Placebo | AEs Leading to Study Discontinuation | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06634797/results